Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | CYSLTR2 | Q9NS75 | 9/20 | 0.43 |
| ▸ | CYSLTR1 | Q9Y271 | 9/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL706042 | 0.86 | ADRA2A (0.43) | ADRA2AADRA2BADRA2CCYSLTR2CYSLTR1 | |
| SCHEMBL5665256 | 0.82 | CYSLTR2 (0.46) | ADRA2AADRA2BADRA2CCYSLTR2CYSLTR1 | |
| SCHEMBL9621646 | 0.82 | CYSLTR2 (0.46) | ADRA2AADRA2BADRA2CCYSLTR2CYSLTR1 | |
| SCHEMBL30436245 | 0.82 | CYSLTR2 (0.46) | ADRA2AADRA2BADRA2CCYSLTR2CYSLTR1 | |
| SCHEMBL3482119 | 0.81 | CYSLTR2 (0.47) | ADRA2AADRA2BADRA2CCYSLTR2CYSLTR1 | |
| SCHEMBL8750403 | 0.80 | MAPT (0.41) | ADRA2AADRA2BADRA2CCYP3A4CYP2D6 | |
| SCHEMBL8971247 | 0.80 | CYSLTR2 (0.52) | CYSLTR2CYSLTR1LIPGALOX5PTGS2 | |
| SCHEMBL5932304 | 0.79 | CYSLTR2 (0.48) | CYSLTR2CYSLTR1LIPGCYP3A4CYP2D6 | |
| SCHEMBL16155004 | 0.79 | CYSLTR2 (0.48) | CYSLTR2CYSLTR1LIPGCYP3A4CYP2D6 | |
| SCHEMBL7923490 | 0.79 | CYSLTR2 (0.44) | ADRA2AADRA2BADRA2CCYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3527593-B1 | ISOCYANATE COMPOSITION, METHOD FOR PRODUCING ISOCYANATE COMPOSITION, AND METHOD FOR PRODUCING ISOCYANATE POLYMER | ASAHI CHEMICAL IND (JP) | 2025-07-23 | — | — | EP | disclosed |
| EP-3527600-B1 | ISOCYANATE COMPOSITION AND PRODUCTION METHOD FOR ISOCYANATE POLYMER | ASAHI CHEMICAL IND (JP) | 2025-07-09 | — | — | EP | disclosed |
| US-20230114799-A1 | ISOCYANATE COMPOSITION AND METHOD FOR PRODUCING ISOCYANATE POLYMER | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2023-04-13 | — | — | US | disclosed |
| US-11548975-B2 | Isocyanate composition and method for producing isocyanate polymer | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2023-01-10 | — | — | US | disclosed |
| US-11118001-B2 | Isocyanate composition, method for producing isocyanate composition, and method for producing isocyanate polymer | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2021-09-14 | — | — | US | disclosed |
| US-11078321-B2 | — | — | 2021-08-03 | — | — | US | disclosed |
| US-20200048403-A1 | ISOCYANATE COMPOSITION, METHOD FOR PRODUCING ISOCYANATE COMPOSITION, AND METHOD FOR PRODUCING ISOCYANATE POLYMER | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2020-02-13 | — | — | US | disclosed |
| EP-3527600-A1 | ISOCYANATE COMPOSITION AND PRODUCTION METHOD FOR ISOCYANATE POLYMER | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2019-08-21 | — | — | EP | disclosed |
| EP-3527593-A1 | ISOCYANATE COMPOSITION, PRODUCTION METHOD FOR ISOCYANATE COMPOSITION, AND PRODUCTION METHOD FOR ISOCYANATE POLYMER | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2019-08-21 | — | — | EP | disclosed |
| US-20190225739-A1 | ISOCYANATE COMPOSITION AND METHOD FOR PRODUCING ISOCYANATE POLYMER | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548975-B2 | Isocyanate composition and method for producing isocyanate polymer | IDH3A, IDH2, IDH3B | ADRA2A 4689/4885ADRA2B 4746/4885ADRA2C 4639/4885 |
| US-11078321-B2 | — | IDH3A, IPO4, F12 | ADRA2A 3064/4885ADRA2B 2803/4885ADRA2C 2989/4885 |
| US-20230114799-A1 | ISOCYANATE COMPOSITION AND METHOD FOR PRODUCING ISOCYANATE POLYMER | IDH3A, IDH2, IDH3B | ADRA2A 4654/4885ADRA2B 4750/4885ADRA2C 4652/4885 |
| US-11118001-B2 | Isocyanate composition, method for producing isocyanate composition, and method for producing isocyanate polymer | IDH3A, IPO4, IDH3B | ADRA2A 4002/4885ADRA2B 3808/4885ADRA2C 3843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.